Annual Activity Report 2025

SITUATION AND ACTIVITIES OF THE COMPANY AND ITS SUBSIDIARIES DURING THE PAST FINANCIAL YEAR

The group’s businesses

Orano Med’s ambition is to develop effective and targeted anti cancer therapies in two strategic areas: ● developing innovative treatments using Orano Med’s lead-212 through scienti fi c partnerships or 100% Orano Med projects; and

● building the production plants necessary to produce these lead-212 treatments in order to meet the needs of current clinical development and the potential future marketing of drugs subject to validation by the health authorities.

ORANO MED’S ONCOLOGY R&D PIPELINE

Program

Indication

Discovery

PoC

Pre-IND Phase 1 Phase 2/3

Partners

2

Neuroendocrine tumors

AlphaMedix TM

Solid tumors (breast and prostate cancer)

212 Pb-GRPR

212 Pb-PSMA

Prostate cancer

Solid tumors

212 Pb CEA-PRIT

212 Pb-DARPin-DLL3 MP0712

Small-cell lung cancer

Solid tumors (including ovarian cancer)

212 Pb DARPin MSLN

212 Pb DARPin

Undisclosed target

Phage display platform

212 Pb-PRRT

Undisclosed target

Phage display platform

Undisclosed target

212 Pb-PRRT

Undisclosed

212 Pb-PRRT

Several targets

Undisclosed

212 Pb-TAT

Several targets

Source: Orano

Batteries Program In 2020, Orano decided to launch the “battery recycling” project by conducting R&D work with CEA Liten to develop an innovative process for recycling Lithium-ion electric vehicle batteries.

A joint research laboratory was created in January 2020, located on the CEA site in Grenoble (France).

45

Orano - Annual Activity Report 2025